| | | | | Präparat | Packungsgrösse | EFP | PP | SB | TK | Zusammensetzung | Zulassungsinhaber | Kat. | | | | |
---|
|
| | FI | | | Tapentadol Sandoz Retard 150 mg | 30 | 48.28 | 68.90 | 10% | | Retard-Tabletten: Tapentadolum 150 mg | Sandoz Pharmaceuticals AG | A+ / SL / SG | FB | | G | |
| | FI | | | Tapentadol Sandoz Retard 150 mg | 60 | 84.98 | 108.85 | 10% | | Retard-Tabletten: Tapentadolum 150 mg | Sandoz Pharmaceuticals AG | A+ / SL / SG | FB | | G | |
| | FI | | CM | Ibuprofen Viatris 400 mg | 20 | 1.56 | 10.95 | 10% | | Filmtabletten: Ibuprofenum 400 mg | Viatris Pharma GmbH | B / SL / SG | FB | | G | |
| | FI | | CM | Ibuprofen Viatris 400 mg | 50 | 3.37 | 12.90 | 10% | | Filmtabletten: Ibuprofenum 400 mg | Viatris Pharma GmbH | B / SL / SG | FB | | G | |
L | | FI | | | Lisdexamfetamin Spirig HC 40 mg | 30 | 46.64 | 67.15 | 10% | | Kapseln: Lisdexamfetamini Dimesilas 40 mg | Spirig HealthCare AG | A+ / SL / SG | FB | | G | |
L | | FI | | I/B | Engerix-B 20 | | 23.66 | 42.15 | 10% | | Injektionssuspension: Hepatitidis b viri Antigenum Adnr 20 µg/ml | GlaxoSmithKline AG | B / SL | FB | | G | |
L | | FI | | | Ruxience 500 mg/50 ml | | 1051.32 | 1159.80 | 10% | | Infusionskonzentrat: Rituximabum 500mg / 50ml | Pfizer AG | A / SL | FB | | G | |
| | FI | PI | | Casgevy 4-13 x 10e6 cells/ml | | PA | PA | k.A. | | | Vertex Pharmaceuticals (CH) GmbH | A | FB | | G | |
| | FI | PI | | Ebvallo | | PA | PA | k.A. | | | Pierre Fabre Pharma SA | A | FB | | G | |
| | FI | | I/B | Engerix-B 20 | 10 | PA | PA | k.A. | | Injektionssuspension: Hepatitidis b viri Antigenum Adnr 20 µg/ml | GlaxoSmithKline AG | B | FB | | G | |
| | FI | | | Xenpozyme 4 mg | | PA | PA | k.A. | | poudre pour solution à diluer pour perfusion: Olipudasum Alfa 4 mg | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
| | FI | | | Xenpozyme 4 mg | 10 | PA | PA | k.A. | | poudre pour solution à diluer pour perfusion: Olipudasum Alfa 4 mg | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
| | FI | | | Xenpozyme 20 mg | | PA | PA | k.A. | | poudre pour solution à diluer pour perfusion: Olipudasum Alfa 20 mg | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
| | FI | | | Xenpozyme 20 mg | 10 | PA | PA | k.A. | | poudre pour solution à diluer pour perfusion: Olipudasum Alfa 20 mg | Sanofi-Aventis (Suisse) SA | A | FB | | G | |
L | | FI | PI | | Emtricitabin-Tenofovir- Mepha | 30 | 42.33 | 72.00 | 10% | | Filmtabletten: 2 Wirkstoffe | Mepha Pharma AG | ● A / SL / SG | FB | | G | |
L | | FI | PI | | Emtricitabin-Tenofovir- Mepha | 30 | 42.33 | 72.00 | 10% | | Filmtabletten: 2 Wirkstoffe | Mepha Pharma AG | ● A / SL / SG | FB | | G | |
L | | FI | PI | | Rivaroxaban-Mepha 10 mg | 14 | 9.40 | 19.35 | 10% | | Filmtabletten: Rivaroxabanum 10 mg | Mepha Pharma AG | B / SL / SG | FB | | G | |
L | | FI | PI | | Rivaroxaban-Mepha 10 mg | 28 | 18.81 | 36.95 | 10% | | Filmtabletten: Rivaroxabanum 10 mg | Mepha Pharma AG | B / SL / SG | FB | | G | |
L | | FI | PI | | Rivaroxaban-Mepha 10 mg | 98 | 69.13 | 91.65 | 10% | | Filmtabletten: Rivaroxabanum 10 mg | Mepha Pharma AG | B / SL / SG | FB | | G | |
L | | FI | PI | | Rivaroxaban-Mepha 10 mg | 100 | 70.54 | 93.10 | 10% | | Filmtabletten: Rivaroxabanum 10 mg | Mepha Pharma AG | B / SL / SG | FB | | G | |
L | | FI | | | Binocrit 8000 IE/0,8 ml | 6 x 0.8 ml | 297.96 | 340.45 | 10% | | Injektionslösung in Fertigspritze: Epoetinum Alfa 8000U.I. / 0.8ml | Sandoz Pharmaceuticals AG | A / SL | FB | | G | |
L | | FI | PI | | Enbrel 25 mg | Set(s) | 405.49 | 455.15 | 10% | | Lyophilisat und Lösungsmittel: Etanerceptum 25 mg | Pfizer AG | B / SL | FB | | G | |
| | FI | | | Moviprep Orange | 2 Sachet(s) | 11.51 | 28.95 | 10% | | Pulver: 4 Wirkstoffe Pulver: 2 Wirkstoffe | Norgine AG | B / SL | FB | | G | |
L | | FI | | | Bavencio 200 mg/10 ml | | 827.76 | 916.65 | 10% | | Infusionskonzentrat: Avelumabum 200mg / 10ml | Merck (Schweiz) AG | A / SL | FB | | G | |
L | | FI | | | Bavencio 200 mg/10 ml | 4 | 3311.04 | 3617.35 | 10% | | Infusionskonzentrat: Avelumabum 200mg / 10ml | Merck (Schweiz) AG | A / SL | FB | | G | |
L | | FI | | | Vegzelma 100 mg/4 ml | | 257.57 | 296.55 | 10% | | Infusionskonzentrat: Bevacizumabum 100mg / 4ml | iQone Healthcare Switzerland SA | A / SL | FB | | G | |
L | | FI | | | Vegzelma 400 mg/16 ml | | 962.84 | 1063.55 | 10% | | Infusionskonzentrat: Bevacizumabum 400mg / 16ml | iQone Healthcare Switzerland SA | A / SL | FB | | G | |
L | | FI | | PS | Herceptin subkutan 600mg/5ml | | 1484.04 | 1630.40 | 10% | | Lösung zur subkutanen Injektion: Trastuzumabum 600mg / 5ml | Roche Pharma (Schweiz) AG | A / SL | FB | | G | |
L | | FI | | | Ogivri 150 mg | | 456.84 | 513.25 | 10% | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Trastuzumabum 150 mg | Medius AG | A / SL | FB | | G | |
| | FI | PI | | Bilaxten 6 mg / ml | 5 ml | PA | PA | k.A. | | Augentropfen: Bilastinum 6 mg/ml | A. Menarini GmbH | B | FB | | G | |
| | FI | PI | | Aspégic 100 | 20 Sachet(s) | PA | PA | k.A. | | Pulver: DL-Lysini Acetylsalicylas 180 mg | Opella Healthcare Switzerland AG | D | FB | | G | |
| | FI | PI | | Aspégic 100 | 100 Sachet(s) | PA | PA | k.A. | | Pulver: DL-Lysini Acetylsalicylas 180 mg | Opella Healthcare Switzerland AG | B | FB | | G | |
| | FI | PI | | Aspégic 500 | 20 Sachet(s) | PA | PA | k.A. | | Pulver: DL-Lysini Acetylsalicylas 900 mg | Opella Healthcare Switzerland AG | D | FB | | G | |
| | FI | PI | Ph | Bronchostop Duo Hustensaft | 120 ml | PA | PA | k.A. | | Lösung (oral): 2 Wirkstoffe | Hänseler AG | D | FB | | G | |
| | FI | PI | Ph | Bronchostop Duo Hustensaft | 200 ml | PA | PA | k.A. | | Lösung (oral): 2 Wirkstoffe | Hänseler AG | D | FB | | G | |
| | FI | | I/B | VeraSeal 2 ml | 2 x 1 ml | PA | PA | k.A. | | Lösung für Gewebekleber: Fibrinogenum Humanum 80 mg/ml Lösung für Gewebekleber: Thrombinum Humanum 500 UI/ml | Janssen-Cilag AG | B | FB | | G | |
| | FI | | I/B | VeraSeal 4 ml | 2 x 2 ml | PA | PA | k.A. | | Lösung für Gewebekleber: Fibrinogenum Humanum 160mg / 2ml Lösung für Gewebekleber: Thrombinum Humanum 1000U.I. / 2ml | Janssen-Cilag AG | B | FB | | G | |
| | FI | | I/B | VeraSeal 6 ml | 2 x 3 ml | PA | PA | k.A. | | Lösung für Gewebekleber: Fibrinogenum Humanum 240mg / 3ml Lösung für Gewebekleber: Thrombinum Humanum 1500U.I. / 3ml | Janssen-Cilag AG | B | FB | | G | |
| | FI | | I/B | VeraSeal 10 ml | 2 x 5 ml | PA | PA | k.A. | | Lösung für Gewebekleber: Fibrinogenum Humanum 400mg / 5ml Lösung für Gewebekleber: Thrombinum Humanum 2500U.I. / 5ml | Janssen-Cilag AG | B | FB | | G | |
| | FI | | | Mylotarg 5 mg | | PA | PA | k.A. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Gemtuzumabum Ozogamicinum 5 mg | Pfizer AG | A | FB | | G | |
| | FI | | | Padcev 20 mg | | 681.24 | 798.45 | k.A. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Enfortumabum Vedotinum 20 mg | Astellas Pharma AG | A | FB | | G | |
| | FI | | | Padcev 30 mg | | 1028.09 | 1189.05 | k.A. | | Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Enfortumabum Vedotinum 30 mg | Astellas Pharma AG | A | FB | | G | |